Lecanemab: clinical trials recruiting now
3
Recruiting trials
2
Conditions studied
1
US states with sites
2
Countries
FDA drug label
- FDA-approved
- Yes. Lecanemab appears in the FDA drug-label database. Marketed as LEQEMBI, LECANEMAB AUTOINJECTOR.
- Drug class
- Amyloid Beta-directed Antibody (FDA established pharmacologic class)
- Mechanism of action
- Amyloid Beta-directed Antibody Interactions (as stated on the FDA label)
- Boxed warning
- The FDA label for Lecanemab carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. ( 1 )
Phase breakdown
Phase 3 1
Phase 4 1
Not applicable 1
Conditions being studied
| Condition | Trials |
|---|---|
| Alzheimer's Disease · Lecanemab for Alzheimer's Disease | 3 |
| Alzheimer Disease | 2 |
Recruiting trials involving Lecanemab
- Cognitive Neurology Unit Clinical Registry
- Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
- Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers
Common questions
Is Lecanemab FDA-approved?
Yes, marketed as LEQEMBI, LECANEMAB AUTOINJECTOR. Its FDA label carries a boxed warning.
How many recruiting trials involve Lecanemab?
3 recruiting trials across 2 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.